Purpose: To evaluate whether 2-deoxy-2-[
Introduction
T o date, neoadjuvant chemotherapy (NAC) has not been associated with survival benefits in the treatment of head and neck squamous cell carcinoma (HNSCC). A meta-analysis of chemotherapy for head and neck cancer (MACH-NC) found no survival advantage in all but two of 31 NAC studies [1] . An updated MACH-NC report that compared chemotherapy timings relative to radiotherapy in randomized trials concluded that the concomitant use of chemotherapy was more beneficial than the induction use [2] .
However, even with the absence of survival benefits, several reports found significant correlations between the response to chemotherapy and subsequent radiation therapy [3] [4] [5] , and suggested that the NAC response is able to predict such a response to radiation therapy. Accurate estimation, including differentiation between responders and non-responders, could lead to appropriate patient management and the avoidance of unnecessary surgical intervention in responders, thus contributing to organ preservation.
Although tissue confirmation (histopathologic response) is considered the gold standard for NAC assessment, observation of tumor morphological changes using anatomical imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) has been used clinically for evaluating NAC responses [3] [4] [5] . Response evaluation criteria in solid tumors [6] and revised guidelines [7] offer assessments of tumor response based on changes in tumor size.
Whether the clinical response reflects the actual histopathologic response is not certain. Dissolving and shrinkage of a tumor mass is the final step in a complex cascade of cellular and sub-cellular changes after initiation of treatment. Morphologic changes may not precisely correlate with changes in cytological tumor viability, so the clinical response according to CT or MRI should not be substituted for the histopathologic response.
The precise estimation of histopathologic response is considered necessary in order to perform organ-preserved therapy, but this requires a complete surgical resection of related organs. If a more precise prediction of the histopathologic response to NAC could be achieved by a noninvasive modality, the response to subsequent radiation therapy may also be more precise, thus contributing to organ preservation.
Positron emission tomography (PET) with 2-deoxy-2-[ 18 F]fluoro-D-glucose (FDG), an analog of glucose, is widely used in oncology. In particular, FDG-PET has been shown to be clinically useful for head-and-neck cancer staging [8] , the detection of simultaneous cancers in different organs [9] , and the search for an unknown primary tumor presenting with cervical metastases [10] . FDG-PET has also aided the assessment of chemotherapy and radiotherapy efficacy, since it allows therapeutic effects to be evaluated at an earlier stage than conventional morphological modalities, such as CT and MRI [11, 12] . Histopathologic responses to NAC have been predicted with high accuracy by FDG-PET in estimated reductions of FDG uptake in esophagogastric junction cancer [13] , gastric cancer [14] , and soft tissue sarcoma [15] . FDG-PET may also have the potential to become a good clinical modality in predicting histopathologic responses to NAC in HNSCC. Should this be the case, it would improve the choice of definitive therapy in HNSCC.
In the current study, we retrospectively evaluated the efficacy of FDG-PET/CT, comparing it with morphological changes evaluated by MRI, for predicting the histopathologic response to NAC. From August 2005 to April 2009, 56 consecutive previously  untreated HNSCC patients in almost stage III or IV (UICC 2002) were treated with one NAC cycle of nedaplatin (CDGP) and TS-1 (S-1) [16] . After NAC was completed, either surgical treatment or radiotherapy was carried out as the subsequent definitive therapy. The choice of definitive therapy was determined by the following criteria, and the imaging studies, i.e., PET and MRI, were not used to make treatment decisions. Surgical treatment was employed when tumors in the T1/T2 stage were resectable by a transoral approach or tumors were in the T3/T4 stage, while radiotherapy was considered when tumors in the T1/T2 stage were not resectable by a transoral approach, patients rejected surgical treatment, or tumors were inoperable. Sixteen patients underwent surgery and the remaining 40 patients underwent radiation therapy after NAC. Thirteen of the patients who underwent surgery received additional radiotherapy.
Materials and Methods

Patient Study Group
The surgically resected specimens of these 16 patients were examined. For patients who had multiple metastatic lymph nodes, the largest one before NAC was taken for analysis as a representative node for each patient. Patient characteristics are summarized in Table 1 . The subjects consisted of 13 males and three females with an age range of 50-74 years and a median age of 58 years. Patient no.13 (hypopharyngeal cancer; T2N3M0) had radical neck dissection followed by chemoradiation with no surgery for the primary lesion. We registered 26 lesions, which included 15 primary lesions and 11 representative lymph nodes. All were proven to be histopathologically positive and were assessed by FDG-PET/CT and MRI before and after NAC. Written informed consent for PET studies was obtained from all patients.
Neoadjuvant Chemotherapy
Standard NAC consisted of one cycle of S-1 (80 mg/m 2 , on days 1-14) followed by CDGP (80 mg/m 2 on day 8). CDGP is a platinum complex with less renal and gastrointestinal toxicity than cisplatin, and S-1 is an oral fluoropyrimidine derivative that has been developed to circumvent problems associated with protracted intravenous infusion of 5-fluorouracil (5-FU), such as hand-foot syndrome and gastritis. S-1 combines tegafur, an oral pro-drug of 5-FU, with two modulators of 5-FU metabolism, the reversible inhibitor of dihydropyrimidine dehydrogenase 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, in a molar ratio of 1:0.4:1. Surgical resection of the tumor was performed 3-4 weeks after completion of chemotherapy.
Imaging Studies
All patients underwent both FDG-PET/CT and MRI with intravenous contrast twice, just before NAC and 2-4 weeks after its completion. The average duration between pre-therapy PET scan and the beginning of NAC was 3.1 days, ranging from 1 to 8 days, and the average duration between the completion of NAC and posttherapy PET scan was 20.5 days, ranging from 14 to 32 days.
PET/CT scanning was performed using a combined PET/CT scanner (Discovery ST Elite-Performance, GE Healthcare or Biograph Duo LSO scanner, Siemens). Patients fasted for at least 4 h before administration of FDG. Data acquisition started approximately 50 min after the injection of a standard dose of 200-250 MBq FDG. Initially, starting at the level of the thigh, lowdose CT scans were acquired with the following parameters: 40-60 mA, 120 kV, 0.6-s tube rotation, 3.75-mm section thickness. Immediately after CT, a PET emission scan was acquired, with an acquisition time of 2 min per bed position. The total acquisition time was approximately 20 min. CT data were used for attenuation correction, and images were reconstructed using the three-dimensional iterative reconstruction algorithm. The sequential PET/CT scans before and after NAC were performed using the same scanner for each patient.
Diagnostic MR scans were performed in all patients, using a 1.5 T scanner (Excelart Vantage, Toshiba Medical Systems, Otawara, Japan). Transaxial and coronal slices of T1-weighted images, coronal slices of T2-weighted images with fat saturation technique using STIR, transaxial slices of T2-weighted images, transaxial and coronal slices of T1-weighted images with contrast enhancement using Gadodiamide, and axial slices of diffusionweighted images were obtained.
PET/CT and MR images were evaluated by a board-certified, radiologist/nuclear medicine physician.
Evaluation of Clinical Response to NAC by Imaging Studies
FDG-PET/CT and MRI evaluated a clinical response to NAC with intravenous contrast using the following quantitative values.
To evaluate PET images, the FDG uptake was semi-quantitatively assessed using a maximum standardized uptake value (SUV max ) calculated in regions of interest. The difference between the pre-chemotherapy SUV max and the post-chemotherapy SUV max was obtained for each lesion. The %changes in SUVs were calculated as follows:
%decrease in SUV max ¼ preÀchemotherapy SUV max À postÀchemotherapy SUV max preÀchemotherapy SUV max Â 100 
Evaluation of Histopathologic Response to NAC by Surgical Specimens
Histopathologic responses of 26 resected specimens were evaluated by two pathologists (UY and IY), who were not informed of PET/ CT and MRI data. Grading of histopathologic regression in tumor beds was performed according to Becker et al. [17] : grade 1a, complete tumor regression; grade 1b, less than 10% vital tumor seen in tumor bed; grade 2, 10-50% residual tumor seen in tumor bed; grade 3, more than 50% remaining residual tumor seen in tumor bed. Specimens with grade1a or grade1b responses were regarded as histopathologic responders while those with grade 2 or 3 were considered histopathologic non-responders. This classification was made prior to data analysis. In addition to the lesion-by-lesion analysis, a patient-based analysis was also performed. The largest lesion of either a primary tumor or a lymph node in the pre-therapy was defined as an "index lesion" for each patient and the histopathologic response of the index lesion was assessed in a patient-based analysis.
Statistical Analysis
The diagnostic accuracy of FDG-PET/CT and MRI in the assessment of histopathologic response to NAC was compared by calculating the area under receiver operating characteristic (ROC) curves [18] . This ranges from 0.5 (random guessing) to 1.0 (perfect test). The area under curve (AUC), sensitivities, specificities, and positive and negative predictive values were calculated. Paired and unpaired comparisons between quantitative parameters were made by t tests and the differences for which PG0.01 were considered to be significant. All statistical analyses were performed with SPSS software (Dr. SPSS II for Windows, Tokyo).
Results
Toxicity
The major grade 3-4 toxicities were neutropenia (19%) and thrombocytopenia (19%).
Grade 2 anemia was seen at a 19% incidence. All hematological toxicities were transient and no treatmentrelated deaths occurred during the study.
FDG-PET/CT
Surgical specimen characteristics are summarized in Table 2 . Mean pre-chemotherapy SUV max of the 26 lesions was 13± 6.8 (mean ± SD). In the post-chemotherapy PET scan, mean SUV max decreased to 9.1±5.9 (PG0.001). Mean reduction rate of SUV max was 30±28%.
MRI
Surgical specimen characteristics are summarized in Table 2 . Mean pre-chemotherapy diameter max was 30±15.0 mm and mean reduction rate of diameter max was 6.5±21%. In the post-chemotherapy MRI scan, mean diameter max decreased to 27±12 mm (PG0.01).
Histopathologic Response Evaluation
Seven specimens were histopathologic responders (three grade 1a and four grade 1b) and the remaining 19 specimens were histopathologic non-responders (three grade 2 and 16 grade 3).
Diagnostic Accuracy of FDG-PET/CT and MRI
Comparisons between histopathologic responders and nonresponders are summarized in Table 3 . None of the MRI parameters showed significant differences between the two groups, while only post-chemotherapy SUV max and % decrease in SUV max showed significant differences (3.6± 2.3 vs. 11±5.6, PG0.001 and 61±15% vs. 18±22, PG0.001, respectively).
ROC analysis revealed that FDG-PET/CT findings of post-chemotherapy SUV max and %decrease in SUV max could predict histopathologic responses (AUC 0.89 and 0.97, P=0.003 and G0.001, respectively; Fig. 1 ). Using a cut-off point of 3.5 (when post-chemotherapy SUV max ≤ 3.50) or 55.5% (when %decrease in SUV max ≥55.5%), histopathologic response could be predicted with a sensitivity of 71% and 86%, a specificity of 89% and 95%, a positive predictive value of 71% and 86%, and a negative predictive value of 89% and95%, respectively. A decrease in SUV max by 55.5% was the best predictor of histopathologic response. By contrast, MRI findings of pre-chemotherapy diameter max , post-chemotherapy diameter max and %decrease in diameter max could not predict histopathologic responses (AUC 0.62, 0.74 and 0.71, P = 0.12, 0.10 and 0.11, respectively; Fig. 1 ). MRI and PET/CT images from representative histopathologic responder and non-responder patients are shown in Figs. 2 and 3 , respectively.
Evaluation of Histopathologic Response to NAC by Patient-based Analysis
In a patient-based analysis, four patients were histopathologic responders (one grade 1a and three grade 1b) and the remaining 12 patients were histopathologic non-responders (three grade 2 and nine grade 3). Comparisons between histopathologic responder and non-responder are summarized in Table 4 . Pre-and post-chemotherapy diameter max or %decrease in diameter max did not significantly differ between the responder and the non-responder, while post-chemotherapy SUV max and %decrease in SUV max showed significant differences between the two groups (3.4±1.0 vs. 12±5.3, p=0.005 and 64±20 vs. 23±23, p=0.007, respectively).
Discussion
Several previous reports found that HNSCC patients achieving a clinical CR after NAC had a significantly better survival rate compared to those with residual disease [19, 20] . However, histopathologic CR, which predicts patients' survival better than clinical CR [21, 22] , is found in only 40-50% of HNSCC patients achieving clinical CR after NAC [20, 21] .
Al-Kourainy et al. reported that HNSCC patients who achieved CR both clinically and histologically had superior survival compared with those who achieved only clinical CR, and were subsequently found to have residual tumors in their surgically resected specimens (P=0.01) [21] . With regard to predicting further response to subsequent radiotherapy, it is not always essential to achieve histopathological CR after NAC. Ensley et al. showed that HNSCC patients achieving clinical partial response (PR) after two cycles of cisplatin-based NAC had better responses to subsequent radiotherapy than those that did not achieve clinical PR [5] , while Clark et al. observed that the locoregional failure rate in patients with clinical CR after two cycles of NAC (cisplatin, bleomycin, and methotrexate/ leucovorin) did not correlate with the presence or absence of microscopic residual disease. They concluded that the goal of NAC may be the achievement of clinical CR rather than histopathologic CR, and that the majority of patients who have clinical CR can be successfully managed with radiotherapy alone [23] .
These studies suggest that even conventional imaging modalities are useful in predicting the efficacy of subsequent radiotherapy when they are performed after two courses of chemotherapy [5, 24] . Earlier assessment, however, is desirable to discontinue chemotherapy for non-responders in order to avoid unnecessary chemotherapy and its side effects.
FDG-PET/CT may play an important role in the evaluation of early tumor responses to NAC, detecting changes in tumor metabolism during chemotherapy before the occurrence of morphological changes [11, [13] [14] [15] 23] . Dalsaso et al. [11] assessed 19 HNSCC patients who underwent NAC (two or three cycles of paclitaxicel and carboplatin) using tissue biopsies taken before and after the NAC. Three patients were classified as histopathologic CR and the Fig. 3 . A 74-year-old woman with hypopharyngeal cancer (T4aN2bM0) (Patient No.9) underwent FDG-PET/CT and MRI scans before (a) and after (b) NAC. White arrows indicate the primary hypopharyngeal lesion. Both the diameters max and SUV max were almost comparable between the two studies (0% and -7%, respectively). The histopathologic regression is Grade 3, with more than 50% residual tumor remaining in the tumor bed. However, the possibility of false-negative results from biopsy specimen sampling errors should not be ruled out.
The current study showed that FDG-PET/CT could predict histopathologic response to NAC in HNSCC patients after only one cycle of NAC with a higher accuracy than MRI. Though the clinical significance of early NAC monitoring with FDG-PET/CT may not be confirmed until survival benefits by PET-guided therapeutic interventions are demonstrated, this modality could be useful in predicting NAC outcome at an early stage, allowing for a more individualized treatment approach.
The optimal timing for follow-up FDG PET/CT after NAC has not yet been established. In patients with high-grade malignant lymphoma, a mean decrease in FDG uptake by more than 45% was observed within 24 h after the administration of the first dose of chemotherapy [25] . On the other hand, Bjurberg et al. reported an early transient increase in FDG uptake in tumor cells of nude mice with a xenografted SCC cell line originating from a human HNSCC within 24 h in tumors treated by cisplatin, followed by a rapid decrease with subsequent tumor regression. This transient increase was described as a "metabolic flare" and thought to consist of two effects: an increased metabolism due to cellular stress and an influx of FDG due to damaged cellular membranes [26] .
In patients with other solid tumors [13] [14] [15] , a change in FDG uptake within 14-20 days after completion of NAC has been found to provide the highest accuracy for prediction of histopathologically subtotal tumor regression. For this reason, we examined post-chemotherapy FDG-PET/CT about 3 weeks after completion of NAC. This timing may correspond with an absence of "flare" and enable the modification of initial therapy plans if required.
The criteria for defining early metabolic responses to NAC with FDG-PET in HNSCC have not yet been established. Some reports demonstrate that a more than 35% reduction in SUV max predicts histopathologic responses of other cancers to NAC with substantial accuracy, based on investigations of surgical specimens as summarized in Table 5 [13] [14] [15] . Our current results are comparable with this, as we observed histopathologic responses predicted with a sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 84%, 70%, and 100%, respectively, when the decrease in SUV max was greater than 35.5% in lesion-by-lesion analysis (Fig. 1) .
Thus, as has been shown in other solid tumors [27], effective histopathological responses are expected when decreases of SUV max exceed 35% at the second or third week after completion of NAC. However, although high sensitivity (100%) can be achieved with these criteria, specificity and positive predictive values are relatively low. Se sensitivity, Sp specificity, na not available Awareness of false-positive cases is essential, because if radiotherapy is performed instead of surgery, tumor relapse is likely to occur, requiring salvage surgery with a high risk of postoperative complications. According to ROC analysis, the cut-off point of 55.5% demonstrated the highest diagnostic accuracy with a sensitivity, specificity, positive predictive value, and negative predictive value of 86%, 95%, 86%, and 95%, respectively. An absolute value of post-chemotherapy SUV max also predicted histopathologic effects with a sensitivity, specificity, positive predictive value, and negative predictive value of 71%, 89%, 71%, and 89%, respectively, using a cut-off point of 3.5. However, some cases (specimens no. 2 and 6) were non-responsive with low (≤3.5) post-chemotherapy SUV max , while one responsive case (specimen no. 22) had a high (93.5) post-chemotherapy SUV max . In specimen no. 2, the maximum diameter of tumor bed was only 2 mm, which might have caused low uptake of FDG due to partial volume effect [28] . In specimen no. 6, a part of the lesion was effective and this is why FDG uptake was relatively low, although it was a nonresponder. On the other hand, in specimen no. 22, the nonviable tumor was located in the inflammatory tonsil, which is why it had a high FDG uptake, although it was a responder. Hawkins et al. [29] also found that SUV max after NAC may remain elevated due to inflammatory infiltrates or reactive fibrosis without the presence of a viable tumor. Estimating the reduction of FDG uptake may, therefore, be more reliable in evaluating NAC responses. In the current population, a decrease in SUV max of ≥55.5% was the best predictor of histopathologic responses.
Conclusion
FDG-PET/CT can predict histopathologic early response to NAC in patients with HNSCC with higher accuracy than MRI. Following one NAC cycle with nedaplatin and S-1, post-chemotherapy SUV max was significantly lower and % decrease in SUV max significantly higher in histopathologic responders than in non-responders, whereas no significant differences were detected in tumor size or its change. Further prospective studies should be performed to determine whether these estimations lead to organ preservation and an overall improved HNSCC patient prognosis.
